JP2025505381A5 - - Google Patents
Info
- Publication number
- JP2025505381A5 JP2025505381A5 JP2024543458A JP2024543458A JP2025505381A5 JP 2025505381 A5 JP2025505381 A5 JP 2025505381A5 JP 2024543458 A JP2024543458 A JP 2024543458A JP 2024543458 A JP2024543458 A JP 2024543458A JP 2025505381 A5 JP2025505381 A5 JP 2025505381A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- combination according
- approximately
- administered
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302834P | 2022-01-25 | 2022-01-25 | |
| US63/302,834 | 2022-01-25 | ||
| PCT/IB2023/000030 WO2023144626A1 (en) | 2022-01-25 | 2023-01-25 | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505381A JP2025505381A (ja) | 2025-02-26 |
| JP2025505381A5 true JP2025505381A5 (https=) | 2026-02-02 |
Family
ID=87470837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543458A Pending JP2025505381A (ja) | 2022-01-25 | 2023-01-25 | フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250120970A1 (https=) |
| EP (1) | EP4469051A4 (https=) |
| JP (1) | JP2025505381A (https=) |
| KR (1) | KR20240138069A (https=) |
| CN (1) | CN118613264A (https=) |
| AU (1) | AU2023210923A1 (https=) |
| CA (1) | CA3249330A1 (https=) |
| CL (1) | CL2024002218A1 (https=) |
| IL (1) | IL314334A (https=) |
| JO (1) | JOP20240162A1 (https=) |
| MA (1) | MA66598A1 (https=) |
| MX (1) | MX2024009168A (https=) |
| TW (1) | TW202339753A (https=) |
| WO (1) | WO2023144626A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2833883A4 (en) * | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| JP7626783B2 (ja) * | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| AU2020444056A1 (en) * | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
-
2023
- 2023-01-25 EP EP23746538.0A patent/EP4469051A4/en active Pending
- 2023-01-25 CN CN202380018679.4A patent/CN118613264A/zh active Pending
- 2023-01-25 KR KR1020247022669A patent/KR20240138069A/ko active Pending
- 2023-01-25 MA MA66598A patent/MA66598A1/fr unknown
- 2023-01-25 CA CA3249330A patent/CA3249330A1/en active Pending
- 2023-01-25 JP JP2024543458A patent/JP2025505381A/ja active Pending
- 2023-01-25 WO PCT/IB2023/000030 patent/WO2023144626A1/en not_active Ceased
- 2023-01-25 IL IL314334A patent/IL314334A/en unknown
- 2023-01-25 US US18/730,930 patent/US20250120970A1/en active Pending
- 2023-01-25 AU AU2023210923A patent/AU2023210923A1/en active Pending
- 2023-01-25 MX MX2024009168A patent/MX2024009168A/es unknown
- 2023-01-30 TW TW112103190A patent/TW202339753A/zh unknown
-
2024
- 2024-07-23 JO JOJO/P/2024/0162A patent/JOP20240162A1/ar unknown
- 2024-07-23 CL CL2024002218A patent/CL2024002218A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| JP2022531939A5 (https=) | ||
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| RS62935B1 (sr) | Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2015500822A5 (https=) | ||
| EP2817011A1 (en) | Treatment of cancer | |
| WO2018026606A1 (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| KR20190068519A (ko) | PIKfyve 억제제를 포함하는 조성물 및 RANK 신호전달의 억제와 관련된 방법 | |
| JPWO2020250915A5 (https=) | ||
| US20050033034A1 (en) | Anti-t cell immunotoxin fusion protein and its therapeutic use | |
| CN105101968A (zh) | 治疗增殖性疾病的组合疗法 | |
| JP2025505381A5 (https=) | ||
| US20210023099A1 (en) | Combination therapy with a bet inhibitor and a proteasome inhibitor | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| Schrijvers et al. | Castration-refractory prostate cancer: new drugs in the pipeline | |
| JP2020172471A (ja) | ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物 | |
| RU2024119934A (ru) | Фармацевтическая композиция, содержащая производное фталазинона, для совместного введения с противораковым лекарственным средством | |
| KR101824205B1 (ko) | 암 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
| JP2004026811A (ja) | ビタミンｄ３誘導体を含有する抗癌作用を増強させるための薬剤 | |
| JP2019524780A (ja) | プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ | |
| HK40125832A (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |